← Leaderboards
Jason A Chesney
University Of Louisville
$5,360,168
Attributed
$6,001,722
Total exposure
11
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3.9M · FY2005–24$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$20,086,069 · 12
By mechanism
P20$16,072,724 · 8
R01$2,537,597 · 2
P30$1,218,827 · 1
R56$256,921 · 1
Top collaborators
- Jun Yan12 shared
- Sharmila Nair2 shared
- Joseph Chen1 shared
Most similar at University Of Louisville
Same institution · by research overlap
- Jun Yan$16,605,525
- Craig J McClain$36,863,296
- Simon Michael Danner$2,784,184
- David S. K. Magnuson$6,325,664
- Aruni Bhatnagar Bhatnagar$35,834,843
Others in their field
Top investigators on “Tumor”
- David Heimbrook · Leidos Biomedical Research, Inc.$636,492,067
- Leonard Freedman · Leidos Biomedical Research, Inc.$360,535,780
- Gregory H Reaman · National Childhood Cancer Foundation$208,276,509
- Richard K. Wilson · Washington University$203,917,615
- Norman Wolmark · Nsabp Foundation, Inc.$177,323,696
- Ronald T Mitsuyasu · University Of California Los Angeles$138,361,819
Research focus
TumorMalignant NeoplasmsGenomicsResponseUniversitiesGrowthInterestLungResourcesMolecular TargetCenters Of Research ExcellenceNovel StrategiesSuccessResistanceResearch PersonnelCancer CellImmuneCancer TypeBaseServicesAnimalsDiagnosisProgramsMediating
Grant awards (33)
Center for Cancer Immunology and Immunotherapy (CCII)$2,292,575
P20 · FY2024 · GM
Center for Cancer Immunology and Immunotherapy (CCII).$947,067
P20 · FY2024 · GM
Leveraging Zika virus driven myeloid cell responses to treat GBM$220,840
P20 · FY2024 · GM
TBD$217,147
P20 · FY2024 · GM
The role of ECM-mediated mechanosignaling on regional immunosuppression in GBM$213,030
P20 · FY2024 · GM
Center for Cancer Immunology and Immunotherapy (CCII)$2,305,905
P20 · FY2023 · GM
Center for Cancer Immunology and Immunotherapy (CCII)$260,726
P20 · FY2023 · GM
TBD$248,337
P20 · FY2023 · GM
TBD$235,580
P20 · FY2023 · GM
Leveraging Zika virus driven myeloid cell responses to treat GBM$148,174
P20 · FY2023 · GM
Center for Cancer Immunology and Immunotherapy (CCII)$2,316,025
P20 · FY2022 · GM
Surveillance and identification of variants of concern within circulating SARS-CoV-2 across Kentucky$521,245
P20 · FY2022 · GM
Center for Cancer Immunology and Immunotherapy (CCII)$2,324,733
P20 · FY2021 · GM
Surveillance and identification of variants of concern within circulating SARS-CoV-2 across Kentucky$778,440
P20 · FY2021 · GM
Center for Cancer Immunology and Immunotherapy (CCII)$2,337,631
P20 · FY2020 · GM
Animal Model Core$235,461
P30 · FY2017 · GM · contact PI
Animal Model Core$241,773
P30 · FY2016 · GM · contact PI
Activation of Cyclin-Dependent Kinases by Fructose-2,6-Bisphosphate$311,250
R01 · FY2015 · CA · contact PI
Animal Model Core$256,949
P30 · FY2015 · GM · contact PI
Activation of Cyclin-Dependent Kinases by Fructose-2,6-Bisphosphate$301,913
R01 · FY2014 · CA · contact PI
Animal Model Core$249,183
P30 · FY2014 · GM · contact PI
Activation of Cyclin-Dependent Kinases by Fructose-2,6-Bisphosphate$292,575
R01 · FY2013 · CA · contact PI
Animal Model Core$235,461
P30 · FY2013 · GM · contact PI
Activation of Cyclin-Dependent Kinases by Fructose-2,6-Bisphosphate$310,732
R01 · FY2012 · CA · contact PI
Activation of Cyclin-Dependent Kinases by Fructose-2,6-Bisphosphate$309,175
R01 · FY2011 · CA · contact PI
Targeting of 6-Phosphofructo-2 kinase in Cancer$256,921
R56 · FY2009 · CA · contact PI
Targeting of 6-Phosphofructo-2 kinase in Cancer$247,753
R01 · FY2008 · CA · contact PI
Targeting of 6-Phosphofructo-2 kinase in Cancer$247,753
R01 · FY2007 · CA · contact PI
COBRE: LOUISVILLE RES FOUND INC: P1: GLYCOLYSIS AND NEOPLASTIC GROWTH$282,721
P20 · FY2006 · RR · contact PI
Targeting of 6-Phosphofructo-2 kinase in Cancer$255,153
R01 · FY2006 · CA · contact PI
Targeting of 6-Phosphofructo-2 kinase in Cancer$261,293
R01 · FY2005 · CA
COBRE: LOUISVILLE RES FOUND INC: P1: GLYCOLYSIS AND NEOPLASTIC GROWTH$198,950
P20 · FY2005 · RR
GLYCOLYSIS AND NEOPLASTIC GROWTH$223,598
P20 · FY2004 · RR